Search

Displaying results 1001 - 1010 of 4233 in total
  1. Drug

    Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB10990
    Approved

    Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received

  2. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    [L53408] As opposed to previously approved COVID-19 mRNA vaccines, including the original Moderna COVID-19 vaccine ([elasomeran]), CX-052075 encodes only the immunodominant regions (NTD and RBD) of … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

  3. Drug

    Grazoprevir

    go.drugbank.com/drugs/DB11575
    Approved

    Grazoprevir is available as a fixed dose combination product with [DB11574] (tradename Zepatier) used for the treatment of chronic Hepatitis C. … Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Grazoprevir.

  4. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … [A262924] On September 25, 2023, tislelizumab gained EMA approval as a monotherapy for adults with esophageal cancer under the brand name TEVIMBRA.

  5. Drug

    Nimodipine

    go.drugbank.com/drugs/DB00393
    ApprovedInvestigational

    Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.

  6. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. … [L149] In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic

  7. Drug

    Pegfilgrastim

    go.drugbank.com/drugs/DB00019
    ApprovedInvestigational

    [A187607] First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection. … [A187601] The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer

  8. Drug

    Duloxetine

    go.drugbank.com/drugs/DB00476
    ApprovedInvestigational

    [label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. … [A178741] Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.

  9. Drug

    Metreleptin

    go.drugbank.com/drugs/DB09046
    ApprovedInvestigational

    [A263126] Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia, insulin resistance, diabetes mellitus, and fatty liver disease. … [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized

  10. Drug

    Colesevelam

    go.drugbank.com/drugs/DB00930
    ApprovedInvestigational

    Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bil...